Platelet Activation Determines Angiopoietin-1 and VEGF Levels in Malaria: Implications for Their Use as Biomarkers by Syafruddin D
Platelet Activation Determines Angiopoietin-1 and VEGF
Levels in Malaria: Implications for Their Use as Biomarkers
Judith Brouwers1., Rintis Noviyanti2., Rob Fijnheer1, Philip G. de Groot1, Leily Trianty2, Siti Mudaliana2,
Mark Roest1, Din Syafruddin2, Andre van der Ven3, Quirijn de Mast1,3*
1Department of Clinical Chemistry and Haematology, University Medical Centre, Utrecht, The Netherlands, 2 Eijkman Institute for Molecular Biology, Jakarta, Indonesia,
3Department of Internal Medicine, Radboud University Nijmegen Medical Centre, The Netherlands
Abstract
Introduction: The angiogenic proteins angiopoietin (Ang)-1, Ang-2 and vascular endothelial growth factor (VEGF) are
regulators of endothelial inflammation and integrity. Since platelets store large amounts of Ang-1 and VEGF, measurement
of circulation levels of these proteins is sensitive to platelet number, in vivo platelet activation and inadvertent platelet
activation during blood processing. We studied plasma Ang-1, Ang-2 and VEGF levels in malaria patients, taking the
necessary precautions to avoid ex vivo platelet activation, and related plasma levels to platelet count and the soluble
platelet activation markers P-selectin and CXCL7.
Methods: Plasma levels of Ang-1, Ang-2, VEGF, P-selectin and CXCL7 were measured in CTAD plasma, minimizing ex vivo
platelet activation, in 27 patients with febrile Plasmodium falciparum malaria at presentation and day 2 and 5 of treatment
and in 25 healthy controls.
Results: Levels of Ang-1, Ang-2 and VEGF were higher at day 0 in malaria patients compared to healthy controls. Ang-2
levels, which is a marker of endothelial activation, decreased after start of antimalarial treatment. In contrast, Ang-1 and
VEGF plasma levels increased and this corresponded with the increase in platelet number. Soluble P-selectin and CXCL7
levels followed the same trend as Ang-1 and VEGF levels. Plasma levels of these four proteins correlated strongly in malaria
patients, but only moderately in controls.
Conclusion: In contrast to previous studies, we found elevated plasma levels of Ang-1 and VEGF in patients with malaria
resulting from in vivo platelet activation. Ang-1 release from platelets may be important to dampen the disturbing effects of
Ang-2 on the endothelium. Evaluation of plasma levels of these angiogenic proteins requires close adherence to a stringent
protocol to minimize ex vivo platelet activation.
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Introduction
The endothelium plays a central role in the pathophysiology of
P. falciparum malaria. Erythrocytes containing mature malaria
parasites adhere to the endothelium via a range of endothelial
receptors in order to escape removal by the spleen. Endothelial
activation is an early feature of malaria, which is likely to favor
sequestration of parasitized erythrocytes [1]. Excessive activation
may contribute to loss of barrier function of the endothelium and
organ dysfunction. Angiogenic proteins are increasingly recog-
nized to be central regulators of endothelial physiology. Vascular
endothelial cell growth factor (VEGF) increases the expression of
adhesion molecules and coagulation factors and increases vascular
permeability [2,3]. Angiopoietins are other important mediators of
angiogenesis. Binding of angiopoietin (Ang)-1 to the Tie2-receptor
on endothelial cells maintains endothelial integrity and reduces the
effects of inflammation [4,5]. In contrast, Ang-2 counteracts the
protective Ang-1 effects and promotes vascular leakage and
inflammation [6,7]. With endothelial cell activation, cytoadher-
ence and microvascular hypoxia as central features of malaria, it
may not come as a surprise that these angiogenic proteins have
been studied extensively in malaria. Circulating levels of these
proteins have been determined in several studies and, collectively,
these studies found reduced Ang-1 levels and elevated Ang-2 levels
in patients with malaria compared to healthy controls, while data
on VEGF varied across studies [8–10]. Additional studies
suggested Ang-1 and Ang-2 to be promising biomarkers to
differentiate cerebral from non-cerebral malaria [11,12].
Both Ang-1 and VEGF are both stored in high quantities in
alpha granules from platelets [13] [14] and this is especially
relevant when circulating blood concentrations are measured. Ex-
vivo platelet activation, which is almost inevitable unless special
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precautions are taken, may falsely increase blood concentrations.
Platelets numbers may also influence plasma concentrations,
which is especially relevant for diseases characterized by throm-
bocytopenia, such as malaria. Indeed, there is increasing evidence
that platelets and their released proteins are important regulators
of endothelial permeability and this may partly be mediated by
these platelet-derived angiogenic proteins [15]. The aim of our
study was to determine plasma levels of VEGF, Ang-1, Ang-2 in
adult Indonesian patients with Plasmodium falciparum malaria from
whom platelet poor plasma was obtained under special conditions
to prevent ex vivo platelet activation. A second aim was to
correlate plasma levels of these angiogenic proteins with circulat-
ing platelet numbers and markers of platelet activation.
Methods
Ethics Statement
This study received ethical clearance for the use of human
subject from the Eijkman Institute Research Ethics Committee,
Jakarta, Indonesia and all enrolled patients gave written informed
consent.
Study Area, Study Population, and Ethics
This study was conducted in the Rumah Sakit Karitas Hospital
in Waitabula, West Sumba, East Nusa Tenggara Province,
Indonesia, an area of hypo- to meso-endemic P. falciparum and
P. vivax malaria transmission. Consecutive patients presenting to
hospital with recent or current fever, clinical symptoms of malaria
and a positive blood slide for P. falciparum were enrolled in this
study following informed consent. All patients were assessed
according to a predefined protocol which included a standardized
history and physical examination performed by an experienced
internist-infectious diseases specialist. All patients were treated
with intravenous quinine and an antipyretic (paracetamol).
Concurrent administration of antibiotics for severely ill patients
was on the discretion of the treating physician. Venous blood for
this study was collected at enrollment and on day two and five
after enrollment. A group of 25 healthy young adults were
recruited among local hospital staff as controls. All controls had no
signs or symptoms of any illness and a negative malaria blood
slide. Treatment for malaria in the past two months was an
exclusion criteria for both malaria patients and controls.
Sample Collection and Laboratory Procedures
Five ml of venous blood was collected in EDTA tubes for a full
blood count and malaria slides and in CTAD tubes (Becton-
Dickinson Vacutainer Systems; tubes containing citrate and the
platelet stabilizing agents theophylline, adenosine, and dipyridam-
ole) for measurement of angiogenic and platelet activation marker
proteins. In vitro platelet activation is almost completely absent in
whole blood anticoagulated with CTAD [16,17]. CTAD blood
tubes from malaria patients and controls were centrifuged within
30 minutes at 2,000 g for 10 minutes and the top fraction of the
plasma was collected, carefully avoiding the buffy coat. The
plasma was frozen at 220uC until shipment to a 280uC freezer at
the Eijkman Institute in Jakarta. A full blood count was
determined by a standard hematology analyzer (Arcus, Diatron,
Vienna, Austria). Thick and thin blood smears were stained with
Giemsa, and the number of parasites was quantified against 200
white blood cells. Parasite density was calculated using the
patient’s white blood cell count. Plasma Ang-1, Ang-2 and VEGF
levels were measured by quantitative sandwich enzyme immuno-
assay technique according to the instructions of the manufacturer
(Quantikine, R&D systems, Minneapolis, USA) at the Eijkman
Institute. The platelet activation markers P-selectin and CXCL7
(beta-thromboglobulin) were measured in the Department of
Clinical Chemistry and Haematology of the University Medical
Center Utrecht as described in detail earlier [18].
Statistical Analysis
Data are presented as median followed by interquartile range in
parentheses unless otherwise stated. Within the group of malaria
patients, the Freidman test with post-tests was used to compare
laboratory parameters on the three time points.Mann-Whitney U
test was used for comparisons with the controls. Relationships
between laboratory parameters were assessed using Spearman
correlation coefficient. All analyses were performed with Graph-
Pad version 5.0.
Table 1. Characteristics of malaria patients and controls.
P. falciparum malaria Healthy controls P value
Number, n 27 25
Age, years 13 (6–26) 24 (22–29) 0.001
Female, n (%) 9 (33) 19 (76) 0.02
Native Sumbanese, n (%) 26 (96) 25 (100) ns
Smoking, n (%) 6 (22) 4 (16) ns
Days illness, days 3 (3–5) NA
Last malaria treatment, months 24 (11.5–60) 48 (24–60) 0.04
Parasite density, parasites/mL 71,203 (22,055–167,560) 0 (0–0)
Platelet count, 109/L 70 (54–112) 360 (266–437) ,0.001
Platelet count ,1506109/L, % 21 (78) 0 (0)
Mean platelet volume, fl 7.2 (6.5–8.0) 6.8 (5.9–7.8) ns
Hemoglobin, g/dL 10.7 (9.4–12.8) 13.3 (12.4–14.1) ,0.001
White blood cell count, 109/L 6.7 (5.4–9.9) 6.9 (6.1–7.3) ns
Shown are medians with interquartile range unless otherwise specified.
ns, not significant (P.0.05); NA, not applicable.
doi:10.1371/journal.pone.0064850.t001
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Results and Discussion
A total number of 27 patients with P. falciparum malaria and 25
controls were included. Demographic and clinical characteristics
are shown in table 1. Compared to the controls, malaria patients
were younger and more often male. Both groups shared the same
genetic background. None of the patients and controls had been
treated for malaria in the past two months or had used medication
in the week before enrollment. Moreover, none had diabetes
mellitus or had suffered from a cardiovascular event or tubercu-
losis in the past. Malaria patients had a significantly lower platelet
count and a lower hemoglobin level. According to WHO-criteria,
two malaria patients were classified as suffering from cerebral
malaria and four as severe malarial anemia.
Figure 1 shows the course of platelet numbers, together with the
course of the angiogenic proteins Ang-1, Ang-2 and VEGF and of
the platelet activation markers P-selectin and CXCL7. As
expected, platelet numbers rose after start of antimalarial
treatment on day 0. Ang-2 is stored in Weibel-Palade bodies in
endothelial cells and is therefore regarded as a marker of
endothelial cell activation. Plasma levels of Ang-2 were elevated
at day 0 and decreased upon start of antimalarial treatment to
levels comparable to those in controls. In contrast, Ang-1 and
Figure 1. Platelet number and plasma levels of angiogenic and platelet activation markers. Levels of angiopoietin-2, angiopoietin-1,
vascular endothelial growth factor (VEGF), soluble P-selectin and CXCL7 were determined in CTAD plasma in 27 patients with febrile P. falciparum
malaria at the start of malaria treatment (day 0), day 2 and day 5 and in 25 healthy controls. Data are presented in a scatter dot plot with median and
interquartile range. Differences between malaria patients in time were assessed by the Friedman’s test; differences with controls with the Mann-
Whitney test. **denotes p,0.01 and *p,0.05.
doi:10.1371/journal.pone.0064850.g001
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VEGF plasma levels were also higher at day 0 compared to levels
in controls, but start of antimalarial treatment resulted in a further
increase in these proteins. The ratio of Ang-2/Ang-1 in the day 0
sample of patients and controls was similar (1.4 vs. 1.3; p = 0.18).
After start of antimalarial treatment, the Ang-2/Ang-1 ratio
declined to 0.5 at day 2 and 0.3 at day 5. the six patients with
severe malaria had a higher median Ang-2/Ang-1 ratio at day 0
(1.5 vs. 0.8) and day 2 (4.7 vs. 0.5), although these differences did
not reach statistical significance.
The time course of Ang-1 and VEGF resembled the course of
the platelet activation markers P-selectin and CXCL7. Correlation
analysis, presented in table 2, showed that both Ang-1 and VEGF
levels in malaria patients were strongly correlated with P-selectin
and especially CXCL7 levels on the three time points. While P-
selectin is released by both activated platelets and endothelial cells,
CXCL7 is exclusively derived from platelets [19]. There was no
significant correlation with either Ang-2, platelets counts or WBC
counts. Moreover, in controls, correlations between Ang-1 and
VEGF and markers of platelet activation were only weak. These
findings suggest that platelet activation is one of the main
determinants of plasma levels of Ang-1 and VEGF in malaria
patients, but not in healthy controls. The fact that VEGF is made
by many different cell types, and its production is upregulated in
hypoxic tissues may explain the weaker correlation of VEGF than
Ang-1 with other platelet activation markers. We have previously
reported that malaria is associated with a normal thrombopoietic
activity [20]. Ongoing peripheral clearance of degranulating
platelets may explain why plasma levels of these platelet-stored
proteins were increased despite the low circulating platelet counts.
The rise in circulating platelet counts following start of antima-
larial treatment together with ongoing platelet degranulation may
also explain the further increase in plasma levels of these proteins,
although no significant correlation of platelets numbers with Ang-
1 and VEGF plasma levels was found. Age did not correlate with
protein levels of any of the measured proteins (data not shown),
suggesting that age difference between malaria patients and
controls did not influence our findings.
These findings are in contrast to previous studies which showed
that patients with malaria had lower Ang-1 levels than healthy
controls [8,9]. Within the group of malaria patients, those with the
most severe illness also had lower levels [11,12]. Data on VEGF in
malaria patients varied more across studies with both higher and
lower levels reported [10,21,22]. Importantly, to our knowledge, in
none of the studies, CTAD or citrate was used as anticoagulant. As
described above, when measuring platelet-stored proteins like
Ang-1 and VEGF, selecting the right anticoagulant and blood
collection and processing techniques is of paramount importance.
If the goal is to assess physiological plasma levels, EDTA or
heparin plasma are less suitable as these anticoagulants are known
to cause various degrees of in vitro platelet activation [23,24,25].
While sodium citrate as anticoagulant already results in a major
reduction in ex vivo platelet activation, CTAD tubes almost
completely prevent in vitro platelet activation and several authors
have already recommended using CTAD when platelet-stored
angiogenesis proteins are being measured [17,25–28]. When these
special measures are not taken, the circulating platelet number
may have a strong impact on measured concentrations of platelet-
stored proteins. Patients with malaria frequently have thrombo-
cytopenia and platelet numbers have been shown to inversely
correlate with severity of illness. Thus, we speculate that the lower
circulating platelet numbers together with variable degrees of ex
vivo platelet activation was responsible for the lower Ang-1 and
VEGF concentrations in previous studies. Serum concentrations of
platelet-stored angiogenic proteins may also have prognostic value.
Generation of serum results in complete in vitro platelet activation
and serum concentrations will largely reflect the total platelet
content of angiogenic proteins. Possible drawbacks of using serum
for this objective is that clotting processes may not release all
platelet-stored angiogenic growth factors into the serum [29] and
that serum concentrations may have no additional prognostic
value over platelet count, as serum concentrations will heavily
depend on platelet counts.
We only used a single centrifugation step to generate platelet
poor plasma in our study, while a double centrifugation step is
often advised. We assumed that only under special circumstances
single centrifugation does not result in near complete removal of
platelets from the top layer of the plasma. We tested this
assumption by centrifuging venous blood in CTAD tubes from
five volunteers using the same procedures as in our study and we
found that a singly centrifugation step resulted in no detectable
platelets in the plasma in four volunteers and a negligible platelet
number (26109/L) in the remaining volunteer.
Several groups of researchers have investigated the utility of
angiopoietins and VEGF as biomarkers to identify patients with
severe malaria. Due to its limited sample size, our study did not
allow to explore the role of these angiogenic proteins in malaria. In
general, we strongly recommend that a similar protocol for
measurement of platelet-stored angiogenic proteins is used in
future biomarker studies, including use of CTAD plasma and
consideration of circulating platelet numbers. These precautions
do not apply to Ang-2, which is derived from endothelial cells and
of which plasma levels are not affected by platelet activation.
What are the implications of these findings for the pathophys-
iology of malaria? Increasing evidence supports a central role for
platelets in protecting the vasculature during inflammation
[15,30,31]. The exact mechanisms are still unclear, but soluble
Table 2. Spearman correlation of angiopoietin-1 and VEGF with other parameters.
Ang-1 VEGF
day 0 day 2 day 5 controls day 0 day 2 day 5 controls
VEGF 0.54` 0.82` 0.84` 2.09
Soluble P-selectin 0.64` 0.87` 0.84` 0.55` 0.48{ 0.60` 0.86` 0.11
CXCL7 0.81` 0.90` 0.95` 0.45{ 0.58` 0.66` 0.89` 2.28
Ang-2 0.07 2.16 0.01 2.03 2.16 2.08 0.31 2.03




Angiogenic Proteins and Platelet Activation
PLOS ONE | www.plosone.org 4 June 2013 | Volume 8 | Issue 6 | e64850
factors released from platelets may play a role [15]. The
angiopoietin-Tie-2 system has evolved as a central regulator of
the activation status and permeability of the vascular lining. An
imbalance in the pro-permeability and pro-inflammatory effects of
Ang-2 and VEGF and the anti-permeability effects of Ang-1,
together with the disrupting effects of pro-inflammatory cytokines
on vascular integrity, may contribute to transient plasma leakage.
Our current data suggest that there is indeed a distortion of this
balance. Ang-1 release from platelets may especially be important
in these circumstances to dampen the disturbing effects of Ang-2
on the endothelium. Since both platelet and endothelial activation
are common in many infectious diseases, the changes in
angiogenic proteins observed in our study may not be specific to
malaria.
In conclusion, we show that platelet activation is an important
determinant of circulating Ang-1 and VEGF levels in malaria.
Optimal biomarkers for malaria severity would rely on inexpensive
point-of-care devices using whole blood. The fact that assays
measuring these platelet-stored angiogenic proteins require special
precautions to avoid inadvertent platelet activation during blood
processing and are prone to artifacts limits widespread use of these
proteins as possible biomarkers.
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